2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Sunday, November 13, 2016

9:00AM-11:00AM: Abstract Number: 4

Rheumatoid Arthritis (RA)-Related Joint Symptoms and Thoracic Bone Mineral Density in an RA-Free Community Dwelling Population

Epidemiology and Public Health - Poster I

9:00AM-11:00AM: Abstract Number: 5

Rheumatoid Arthritis and Periodontitis: Association and Characteristics of Chronic Periodontitis

Epidemiology and Public Health - Poster I

9:00AM-11:00AM: Abstract Number: 566

Rheumatoid Arthritis Patients’ Ability to Accurately Recall DMARD Information Immediately Following an Office Visit with Their Rheumatologist

Rheumatoid Arthritis – Clinical Aspects - ARHP Poster

9:00AM-11:00AM: Abstract Number: 26

Rheumatoid Factor Positivity Increases All-Cause and Cancer Mortality Risk in Korean Healthy Examinees: A Kangbuk Samsung Health Study

Epidemiology and Public Health - Poster I

9:00AM-11:00AM: Abstract Number: 101

Rheumatology Care Utilization and Geographic Distance from Rheumatology Sites within the United States Veteran Affairs Health Care System

Health Services Research - Poster I

9:00AM-11:00AM: Abstract Number: 856

Rho Kinase Ezpression in Giant Cell Arteritis: Validating Perm Intensity Score As a Method of Increasing Sensitivity of Temporal Artery Biopsy

Vasculitis - Poster I: Large Vessel Vasculitis and Polymyalgia Rheumatica

9:00AM-11:00AM: Abstract Number: 773

Risk Factors for Severe Infections in Rituximab Treated Patients: Comparison of Systemic Lupus Erythematosus and Inflammatory Myositis

Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster I: Clinical Trial Design and Current Therapies

9:00AM-11:00AM: Abstract Number: 683

Risk Factors of Uveitis in Ankylosing Spondylitis

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster I: Axial and Peripheral Spondyloarthritis – Clinical Aspects, Imaging and Treatment

9:00AM-11:00AM: Abstract Number: 896

Risk for Cardiovascular Disease in Giant Cell Arteritis and Polymyalgia Rheumatica

Vasculitis - Poster I: Large Vessel Vasculitis and Polymyalgia Rheumatica

9:00AM-11:00AM: Abstract Number: 260

Risk of Cardiovascular Disease Among Patients with Sarcoidosis: A Population-Based Retrospective Cohort Study

Miscellaneous Rheumatic and Inflammatory Diseases - Poster I

9:00AM-11:00AM: Abstract Number: 877

Risk of Coronary Artery Disease in Patients with Polymyalgia Rheumatica: A Systematic Review and Meta-Analysis

Vasculitis - Poster I: Large Vessel Vasculitis and Polymyalgia Rheumatica

9:00AM-11:00AM: Abstract Number: 29

Risk of Vascular Mortality in Seniors with New-Onset Rheumatoid Arthritis

Epidemiology and Public Health - Poster I

9:00AM-11:00AM: Abstract Number: 763

Rituximab As a Corticosteroid-Sparing Agent in Patients with Systemic Lupus Erythematosus

Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster I: Clinical Trial Design and Current Therapies

9:00AM-11:00AM: Abstract Number: 907

Rituximab in Patients with Takayasu Arteritis: A Single Center Experience on Five Patients

Vasculitis - Poster I: Large Vessel Vasculitis and Polymyalgia Rheumatica

9:00AM-11:00AM: Abstract Number: 259

Rituximab in Refractory Cardiac Sarcoidosis – Single Center Experience

Miscellaneous Rheumatic and Inflammatory Diseases - Poster I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].